Saturday 17 October 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 53.1%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
10.78
0.65
−5.69%
Follow BHVN
Biohaven Ltd. (BHVN) P/E ratio
Biohaven Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| Sep 2021 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| BHVN Biohaven Ltd. | n/m |
| SEPN Septerna, Inc. compare | n/m |
| URGN Urogen Pharma compare | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| XNCR Xencor, Inc. compare | n/m |
| NUVB Nuvation Bio Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)